Markets:

Overview

News

Currencies

International

Treasuries

Compugen Ltd. - Ordinary Shares (NQ:CGEN)

2.220 -0.090 (-3.90%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Compugen Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets ↗

October 05, 2026

Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated...

Via MarketBeat

Topics Artificial Intelligence

Compugen (CGEN) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

COM701 interim data expected in Q1 2027 as cash runway extends into 2029.

Via The Motley Fool

Topics Earnings

Compugen Q2 Earnings Call Highlights ↗

August 03, 2026

Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash...

Via MarketBeat

Topics Earnings

Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Beat Sparks 12.73% Pre-Market Rally Amid Clinical Pipeline Progress ↗

May 18, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Earnings Preview For Compugen ↗

March 04, 2024

Via Benzinga

Compugen Q1 Earnings Call Highlights ↗

May 18, 2026

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company...

Via MarketBeat

Topics Earnings

Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Compugen (CGEN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Compugen Ltd (NASDAQ:CGEN) Reports Q3 2025 Earnings Beat, Stock Rises ↗

November 10, 2025

Compugen (CGEN) Q3 2025 earnings beat estimates, with revenue up 26% and a narrower EPS loss. The stock surged 3.7% pre-market on the strong results.

Via Chartmill

Topics Earnings

Q3 Virtual Investor Summit: On-Demand Presentations Now Available

September 30, 2025

Via ACCESS Newswire

Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free

September 16, 2025

Via ACCESS Newswire

Compugen Ltd (NASDAQ:CGEN) Reports Q2 2025 Revenue and EPS Miss, Shares Drop in Premarket ↗

August 06, 2025

Compugen Ltd (CGEN) misses Q2 2025 revenue and EPS estimates, shares drop 2% premarket. Weak financials and clinical progress concerns weigh on investor sentiment.

Via Chartmill

Earnings Scheduled For May 19, 2025 ↗

May 19, 2025

Via Benzinga

Uncovering Potential: Compugen's Earnings Preview ↗

May 16, 2025

Via Benzinga

Earnings Scheduled For March 4, 2025 ↗

March 04, 2025

Via Benzinga

CGEN Stock Earnings: Compugen Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

CGEN stock results show that Compugen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024 ↗

May 20, 2024

CGEN stock results show that Compugen missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023 ↗

March 05, 2024

CGEN stock results show that Compugen missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

7 Speculative Stocks to Double Your Money THIS Year ↗

January 22, 2024

Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.

Via InvestorPlace

Crude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plunge ↗

December 19, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday. The Dow traded up 0.53% to 37,505.25 while the NASDAQ rose 0.51% to 14,980.71. The...

Via Benzinga

Topics Stocks

Earnings Scheduled For March 5, 2024 ↗

March 05, 2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.

Via Benzinga

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 19, 2023

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...

Via Benzinga

Dow Jumps 150 Points; FactSet Shares Rise After Q1 Results ↗

December 19, 2023

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.46% to 37,476.21 while the NASDAQ rose 0.41% to 14,966.74. The S&P 500 also...

Via Benzinga

Topics Stocks

Compugen Ltd. (NASDAQ: CGEN) is One of Tuesday Morning’s Most Active Stocks

December 19, 2023

Via Investor Brand Network

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗

December 19, 2023

Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the

Via Benzinga

Why Are Stocks Up Today? ↗

December 19, 2023

Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday!

Via InvestorPlace

Why Is Compugen (CGEN) Stock Up 189% Today? ↗

December 19, 2023

Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.

Via InvestorPlace

US Stocks Higher; Accenture Issues Weak Sales Outlook ↗

December 19, 2023

U.S. stocks traded higher this morning, with the Dow Jones index gaining around more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.17% to 37,369.84 while the...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.